E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Adult patients with acute myeloid leukemia in complete remission |
|
E.1.1.1 | Medical condition in easily understood language |
Adult patients with acute myeloid leukemia in complete remission |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10046859 |
E.1.2 | Term | Vaccination |
E.1.2 | System Organ Class | 10042613 - Surgical and medical procedures |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10024329 |
E.1.2 | Term | Leukemia |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this trial is to determine the clinical efficacy of WT1 mRNA-electroporated DC vaccination as a post-remission strategy to prevent relapse and prolong overall survival in adult AML patients. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this trial are (i) to assess relapse rate at two years and relapse-free survival to evaluate clinical response, (ii) to monitor molecular and immunological responses and (iii) to evaluate patient-reported outcomes. For the molecular response, the efficacy of the DC vaccine strategy will be determined to control or eradicate minimal residual disease (MRD) in AML. Monitoring of MRD will be performed by sequential measurement of WT1 transcript levels in peripheral blood. For the immunological response, different immunoassays will be used to investigate if the WT1 mRNA-electroporated DC vaccines are immunogenic and capable of inducing anti-leukemic immune responses in vivo. To evaluate patient-reported outcomes, changes in general and disease-specific quality of life will be determined using EQ-5D-5L and QLQ-C30 questionnaires at regular time-points. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Diagnosis of acute myeloid leukemia (AML) according to the 2008 criteria of the World Health Organization (WHO).
o all French-American-British (FAB) subtypes, except: - M3 (acute promyelocytic leukemia)
o all cases of de novo AML or secondary AML with ≥ 20 % blasts in peripheral blood and/or bone marrow, except: - AML secondary to myeloproliferative neoplasms (MPN) - AML secondary to exposure of leukemogenic agents (t-AML), unless treated with CPX-351 chemotherapy or hypomethylating agents combined with venetoclax .
• Completion of one of the following treatment options:
I) Intensive chemotherapy: (1) at least one cycle of induction chemotherapy and one cycle of consolidation chemotherapy (low-dose cytarabine as consolidation therapy is allowed) OR (2) one to two cycles of CPX-351 induction treatment and up to two cycles of CPX-351 consolidation treatment OR II) Low-intensity chemotherapy: (3) at least two cycles to maximum six cycles of hypomethylating agents (HMA) whether or not combined with venetoclax (VEN) (hereafter referred as HMA+/- VEN) OR (4) at least two cycles to maximum six cycles of low-dose cytarabine (LDAC) combined with venetoclax (hereafter referred as LDAC+VEN);
resulting in:
o morphological complete remission (CR), i.e. bone marrow blast count <5% with neutrophil count >1000 cells/µL and platelet count >100,000 cells/µL. OR o morphological complete remission with incomplete blood recovery (CRi), i.e. bone marrow blast count <5% with neutrophil count <1000 cells/µL or platelet count <100,000 cells/µL. For the purpose of this study protocol, platelet count must be >50,000 cells/µL.
• Adult (≥ 18 years) at very high risk of relapse according to: o Age ≥ 60 years, and/or o Adverse biological features (e.g. adverse cytogenetics, adverse morphological features, adverse molecular features, hyperleukocytosis (> 100000 cells/µL)), and o Ineligible for or unwilling to receive hematopoietic stem cell transplantation.
• WHO performance status: grade 0, 1 or 2 at the time of enrollment. For definition of performance status, see: http://www.ecog.org/general/perf_stat.html
• Absence of any psychological, familial, sociological, geographical or physical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before study entry.
|
|
E.4 | Principal exclusion criteria |
• Participation in any other interventional clinical trial during the study period.
• History or concomitant presence of any other malignancy, except for:
o non-melanoma skin cancer o carcinoma in situ of the cervix o any other effectively treated malignancy that has been in remission for >5 years or that is highly likely to be cured at the time of enrollment.
• Concomitant presence of any immunosuppressive disease (e.g. HIV) or any active autoimmune condition, except for vitiligo.
• Concomitant use of systemic corticosteroids in immunosuppressive doses (>1 mg/kg/day of prednisone, or equivalent dose for other corticosteroid preparations) or any other immunosuppressive agent. A minimum of 4 weeks must have elapsed between the last dose of immunosuppressive therapy and the first vaccination. Topical corticosteroids are permitted, except if applied at the sites of DC injection.
• pregnancy or breast-feeding
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary end point: overall surival Clinical response analysis will be performed on all efficacy-evaluable patients according to the ‘Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia’. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Analysis will be performed after inclusion of 130 efficacy-evaluable patients. Study-related follow up of the included patients is intended to be 5 years after the first vaccination. An interim analysis will be performed (i) after inclusion of 49 patients in each group in the study or (ii) after observation of 62 events (total for both groups) or (iii) when 40 patients in each group have at least finished 2 year follow-up or died. |
|
E.5.2 | Secondary end point(s) |
Secondary end point 1 and 2: Clinical response analysis will be performed on all efficacy-evaluable patients according to the ‘Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia’. Secondary endpoins that will be analyzed are relapse-free survival and relapse rate at two years.
Secondary end point 3: Both for the control group and the intervention group, tumor marker levels will be monitored in peripheral blood. This will be done by measuring WT1 mRNA levels using specific primers and quantitative real-time RT-PCR. Molecular response is defined as the normalization of WT1 transcript levels in peripheral blood below background.
Secondary end point 4: Both for the control group and the intervention group, activation of the immune system will be monitored. Peripheral blood samples will be examined by using flow cytometry for functional WT1-specific T cell responses (e.g. WT1-reactive IFN-γ+ T cells), WT1-specific CD8+ T cells (by tetramer analysis in HLA-A*0201+ patients) and changes in lymphocyte subset distribution and activation state.
Secondary end point 5: Patient-reported outcomes: To evaluate changes in general and disease-specific quality of life using EQ-5D-5L and QLQ-C30 questionnaires at regular time points.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary end point 1 and 2: see time point primary endpoint
Secondary end point 3: Monitoring will be done biweekly during the first 4 vaccines, then bimonthly at the time of the booster vaccines (for the control group at similar time points, although no vaccination is given).
Secondary end point 4: Peripheral blood samples will be gathered in the intervention group before the first vaccination (pre-vaccination) and at the time of the fourth vaccination (post-vaccination); and at comparable timepoints in the non-vaccinated control group.
Secondary end point 5: quality of life questionnaires at regular time points. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Control group: no IMP treatment |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 8 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of last subject |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 9 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |